Abstract
Background: The aim of this study was to detail the incidence of venous thromboembolism (VTE) in patients hospitalised with COVID-19 in England.
Methods: This was an exploratory retrospective analysis of observational data from the Hospital Episode Statistics dataset for England. All patients aged ≥18 years in England with a diagnosis of COVID-19 who had a hospital stay that was completed between 1st March 2020 and 31st March 2021 were included. A recorded diagnosis of VTE during the index stay or during a subsequent admission in the six weeks following discharge was the primary outcome in the main analysis. In secondary analysis, VTE diagnosis was the primary exposure and in-hospital mortality the primary outcome.
Results: Over the 13 months, 374,244 unique patients had a diagnosis of COVID-19 during a hospital stay, of whom 17,346 (4.6%) had a recorded diagnosis of VTE. VTE was more commonly recorded in patients aged 40-79 years, males and in patients of Black ethnicity, even after adjusting for covariates. Recorded VTE diagnosis was associated with longer hospital stay and higher adjusted in-hospital mortality (odds ratio 1.35 (95% confidence interval 1.29 to 1.41)).
Conclusions: VTE was a common complication of hospitalisation with COVID-19 in England. VTE was associated with both increased length of stay and mortality rate.
Keywords: COVID-19; Coronavirus; Pulmonary embolism; Thromboembolism.
【저자키워드】 COVID-19, coronavirus, Pulmonary embolism, Thromboembolism, 【초록키워드】 Diagnosis, pulmonary, Venous Thromboembolism, discharge, male, Patient, Retrospective analysis, dataset, mortality rate, incidence, covariates, exploratory, Observational data, England, Admission, in-hospital mortality, Analysis, Odds ratio, VTE, Hospital stay, black, Primary outcome, 95% confidence interval, over, hospitalised, main analysis, subsequent, adjusted, unique, recorded, diagnosis of COVID-19, Hospital Episode Statistics, hospitalisation with COVID-19, with COVID-19, 【제목키워드】 Patient, Thromboembolism, England, hospitalised, with COVID-19,